Upregulation of PITX2 Promotes Letrozole Resistance Via Transcriptional Activation of IFITM1 Signaling in Breast Cancer Cells
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Although the interferon (IFN) signaling and the paired-like homeodomain transcription factor 2 (PITX2) have both been implicated in the progression of breast cancer (BCa), it remains obscure whether these two pathways act in a coordinated manner. We therefore aimed to elucidate the expression and function of PITX2 during the pathogenesis of endocrine resistance in BCa. Materials and Methods PITX2 expression was assessed in BCa tissues using quantitative reverse transcription polymerase chain reaction (RT-qPCR) and immunohistochemistry and in experimentally induced letrozole-resistant BCa cells using RT-qPCR and immunoblotting. Effects of PITX2 deregulation on BCa progression was determined by assessing MTT, apoptosis and xenograft model. Finally, using multiple assays, the transcriptional regulation of interferon-inducible transmembrane protein 1 (IFITM1) by PITX2 was studied at both molecular and functional levels. Results PITX2 expression was induced in letrozole-resistant BCa tissues and cells, and PITX2 induction by IFN signaling powerfully protected BCa cells against letrozole insult and potentiated letrozole-resistance. Mechanistically, PITX2 enhanced IFN-induced AKT activation by transactivating the transcription of IFITM1, thus rendering BCa cells unresponsive to letrozoleelicited cell death. Additionally, ablation of IFITM1 expression using siRNA substantially abolished IFN-elicited AKT phosphorylation, even in the presence of PITX2 overexpression, thus sensitizing BCa cells to letrozole treatment. Conclusion These results demonstrate that constitutive upregulation of PITX2/IFITM1 cascade is an intrinsic adaptive mechanism during the pathogenesis of letrozole-resistance, and modulation of PITX2/IFITM1 level using different genetic and pharmacological means would thus have a novel therapeutic potential against letrozole resistance in BCa.
Abstract
Purpose Although the interferon (IFN) signaling and the paired-like homeodomain transcription factor 2 (PITX2) have both been implicated in the progression of breast cancer (BCa), it remains obscure whether these two pathways act in a coordinated manner. We therefore aimed to elucidate the expression and function of PITX2 during the pathogenesis of endocrine resistance in BCa. Materials and Methods PITX2 expression was assessed in BCa tissues using quantitative reverse transcription polymerase chain reaction (RT-qPCR) and immunohistochemistry and in experimentally induced letrozole-resistant BCa cells using RT-qPCR and immunoblotting. Effects of PITX2 deregulation on BCa progression was determined by assessing MTT, apoptosis and xenograft model. Finally, using multiple assays, the transcriptional regulation of interferon-inducible transmembrane protein 1 (IFITM1) by PITX2 was studied at both molecular and functional levels. Results PITX2 expression was induced in letrozole-resistant BCa tissues and cells, and PITX2 induction by IFN signaling powerfully protected BCa cells against letrozole insult and potentiated letrozole-resistance. Mechanistically, PITX2 enhanced IFN-induced AKT activation by transactivating the transcription of IFITM1, thus rendering BCa cells unresponsive to letrozoleelicited cell death. Additionally, ablation of IFITM1 expression using siRNA substantially abolished IFN-elicited AKT phosphorylation, even in the presence of PITX2 overexpression, thus sensitizing BCa cells to letrozole treatment. Conclusion These results demonstrate that constitutive upregulation of PITX2/IFITM1 cascade is an intrinsic adaptive mechanism during the pathogenesis of letrozole-resistance, and modulation of PITX2/IFITM1 level using different genetic and pharmacological means would thus have a novel therapeutic potential against letrozole resistance in BCa.
참고문헌 (31)
- Hoeflich KP, "The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase", Genes Cancer, 7, pp.73~85 (2016)
- Jelovac D, "Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole", Cancer Res, 65, pp.5380~5389 (2005)
- Brodie AM, "Extending aromatase inhibitor sensitivity in hormone resistant breast cancer", Horm Mol Biol Clin Investig, 5, pp.97~103 (2011)
- Choi HJ, "Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death", Breast Cancer Res, 17, pp.6~ (2015)
- Ariazi EA, "Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time", Proc Natl Acad Sci U S A, 108, pp.18879~18886 (2011)
- Zacharias AL, "Pitx2 is an upstream activator of extraocular myogenesis and survival", Dev Biol, 349, pp.395~405 (2011)
- Dietrich D, "DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients", Diagn Mol Pathol, 21, pp.93~104 (2012)
- Lian ZQ, "Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels", Int J Oncol, 41, pp.629~638 (2012)
- Vasiljevic N, "DNA methylation of PITX2 predicts poor survival in men with prostate cancer", Biomark Med, 8, pp.1143~1150 (2014)
- Zhang JX, "PITX2 : a promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma", Int J Cancer, 132, pp.2567~2577 (2013)
- Lee WK, "Pituitary homeobox 2(PITX2)protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1", Int J Cancer, 133, pp.556~567 (2013)
- Yang Z, "Single-cell sequencing reveals variants in ARID1A, GPRC5A and MLL2driving self-renewal of human bladder cancer stem cells", Eur Urol, 71, pp.8~12 (2017)
- Gu F, "Inference of hierarchical regulatory network of estrogen-dependent breast cancer through ChIP-based data", BMC Syst Biol, 4, pp.170~ (2010)
- Yu T, "miR-1271inhibits ERalpha expression and confers letrozole resistance in breast cancer", Oncotarget, 8, pp.107134~107148 (2017)
- Dong YS, "Unexpected requirement for a binding partner of the syntaxin family in phagocytosis by murine testicular Sertoli cells", Cell Death Differ, 23, pp.787~800 (2016)
- Zhang C, "A chromatin modifier regulates Sertoli cell response to mono-(2-ethylhexyl)phthalate(MEHP)via tissue inhibitor of metalloproteinase 2(TIMP2)signaling", Biochim Biophys Acta, 1839, pp.1170~1182 (2014)
- Zhang Q, "Repression of ESR1 transcription by MYOD potentiates letrozole-resistance in ERalpha-positive breast cancer cells", Biochem Biophys Res Commun, 492, pp.425~433 (2017)
- Ning P, "Role of protein S in castration-resistant prostate cancer-like cells", Endocr Relat Cancer, 23, pp.595~607 (2016)
- Lopez JI, "A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer", APMIS, 125, pp.787~796 (2017)
- Kapoor S, "Promising, new prognostic markers of esophageal carcinomas", APMIS, 121, pp.1011~ (2013)
- Liu Y, "Identification of key genes in endometrioid endometrial adenocarcinoma via TCGA database", Cancer Biomark, 21, pp.11~21 (2017)
- Vela I, "PITX2 and non-canonical Wnt pathway interaction in metastatic prostate cancer", Clin Exp Metastasis, 31, pp.199~211 (2014)
- Wan Abdul Rahman WF, "Expression of DNA methylation marker of paired-like homeodomain transcription factor 2 and growth receptors in invasive ductal carcinoma of the breast", Asian Pac J Cancer Prev, 15, pp.8441~8445 (2014)
- Jezkova E, "Methylation in promoter regions of PITX2and RASSF1A genes in association with clinicopathological features in breast cancer patients", Tumour Biol, 37, pp.15707~15718 (2016)
- Gultekin M, "Metaplastic breast carcinoma : a heterogeneous disease", Asian Pac J Cancer Prev, 15, pp.2851~2856 (2014)
- Khan MS, "Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status", Endocrine, 47, pp.449~455 (2014)
- Zhang JX, "Downregulation of microRNA-644a promotes esophageal squamous cell carcinoma aggressiveness and stem cell-like phenotype via dysregulation of PITX2", Clin Cancer Res, 23, pp.298~310 (2017)
- Torrado M, "A microRNA-transcription factor blueprint for early atrial arrhythmogenic remodeling", Biomed Res Int, 2015, pp.263151~ (2015)
- Cavazzoni A, "Overcoming acquired resistance to letrozole by targeting the PI3K", AKT, Cancer Lett, pp.2012, 323[DOI]
- Lei H, "AKT activation and response to interferon-beta in human cancer cells", Cancer Biol Ther, 4, pp.709~715 (2005)
- Li P, "Coordinated regulation of IFITM1, 2 and 3 genes by an IFNresponsive enhancer through long-range chromatin interactions", Biochim Biophys Acta Gene Regul Mech, 1860, pp.885~893 (2017)